Mountcastle David, Executive Vice President and Chief Financial Officer of Privia Health Group (PRVA), has been a consistent seller of company stock over the past year, with no open-market purchases recorded in his SEC Form 4 filings. Across 48 total transactions, all involving PRVA, his cumulative sales reached approximately $3.72 million, while his acquisition activity was limited exclusively to option exercises and tax-related withholdings—mechanical events that carry no discretionary buying signal. The most recent cluster of activity, spanning July 2026, shows three open-market sales totaling roughly $1.29 million, including a $588,679 disposition on July 9 and a $680,185 sale on July 2.
The pattern is one of steady, periodic liquidation rather than concentrated dumping. Between March and July 2026, Mountcastle executed at least ten open-market sales, with individual values ranging from $16,542 to $680,185. These sales were frequently paired with option exercises (coded "M") on the same or adjacent dates, suggesting a routine process of exercising vested options and immediately selling the underlying shares. For instance, on June 26, he exercised four option tranches valued at $0 and sold shares worth $432,995, while a similar structure appeared on May 4 and May 1, with sales of $30,150 and $179,690 respectively.
Notably, Mountcastle has not reported a single open-market purchase (code "P") during the entire period covered by the filings. His selling bias is unambiguous, but the data offers no insight into whether these transactions reflect portfolio diversification, tax planning, or a view on PRVA's valuation. The absence of any buy-side activity, combined with the regularity of sales tied to option exercises, paints a picture of an executive monetizing equity compensation rather than actively trading on short-term price movements.
AI-assisted summary